EMEA Recommends Ranolazine for Treatment of Chronic Angina
April 25, 2008 - CV Therapeutics reported the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) recommended approval of ranolazine in the European Union (EU) for the treatment of chronic angina.
Following this positive recommendation from the CHMP, CV Therapeutics expects the European Commission to issue full marketing authorization for ranolazine by the end of June. The brand name for ranolazine in the product labeling is Latixa.
The approved indication states that ranolazine "is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists)."
The labeling reflects data from the MERLIN TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with ranolazine. The labeling also notes that the ability of ranolazine to reduce calcium overload is expected to improve myocardial relaxation and decrease left ventricular diastolic stiffness. The doses of the product in the EU will be 375 mg, 500 mg and 750 mg twice daily.
For more information: www.cvt.com
More like this
- Multaq (dronedarone) Recommended for European Approval
- EMEA Approves Plavix Loading Dose for ACS Patients
- New EU Drug Indication Allows Combination With Beta Blockers for Angina
- JAMA Publishes MERLIN TIMI-36 Study — Results Prompt CV Therapeutics to Seek Broader Indication for Angina Tablets
- Study May Hasten New ACS Treatment